Microcap Movers for Monday December 12, 2011

Below are highlights from Benzinga's daily coverage of microcap securities. Benzinga provides comprehensive, objective, and conflict-free coverage of the microcap sector in real-time at BenzingaSmallCap.com. Oxigene Shares of OXiGENE OXGN, the San Francisco, CA clinical-stage biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, rose almost 19% Monday on 7.5 times the average daily volume. OXiGENE and Azanta Danmark A/S announced a partnership agreement to provide access to ZYBRESTAT for the treatment of patients in Europe and Canada with anaplastic thyroid cancer on a compassionate use basis. OXiGENE's newly-formed Named Patient Program, to be managed by Azanta, provides a regulatory mechanism to allow healthcare professionals in Europe and Canada to prescribe ZYBRESTAT to individual ATC patients while it is still in development. OXiGENE shares traded in a range of $1.09 to $1.37 Monday, closing at $1.20. Alimera Sciences Shares of Alimera Sciences ALIM, the Alpharetta, GA biotech company, rose 28% Monday on almost 6 times the average daily volume. A spokesperson for Alimera told Benzinga there was no news to account for the price movement. Alimera Sciences traded in a range of $1.37 to $1.85 Monday and closed at $1.79. Alexza Pharmaceuticals Shares of Alexza Pharmaceuticals ALXA, the Mountain View, CA developer of novel proprietary products for the acute treatment of central nervous system, or CNS conditions, were halted Monday, while an FDA panel met and voted on Alexa's inhaled antipsychotic drug Adasuve. The panel voted 9 to 8 that Adasuve should be approved with strict guidlines. Cannabis Science Shares of Cannabis Science (CBIS), the Denver, CO biotech company, developing pharmaceutical cannabis (marijuana) products, rose 28% today. The company announced a second patient suffering skin cancer is self-administering cannabis extracts in collaboration with Cannabis Science. This patient has photo-documented dramatic results that we will be release to the public once treatment is completed and has been properly vetted by clinical biopsy. Cannabis Science, in conjunction with several Colorado-licensed dispensaries and physicians, consults with a number of cancer patients who were seeking to inform themselves of the current peer-reviewed scientific literature, regarding modern and historical use of cannabis preparations for treating cancers so that they can make informed decisions regarding their self-directed cancer treatment. Cannabis Science traded in a range of $0.01 to $0.02 Monday and closed at $0.02. To get information like this on a streaming basis during the trading day, try a 100% free trial to BenzingaSmallCap.com.